Hitachi Developed Automation Technology of 3D Culture to Expand Regenerative Medicine Business
Support service to establish an automatic manufacturing process for meeting
customer needs will be started
TOKYO, Nov, 27 2019 - (JCN Newswire) - Hitachi, Ltd. (TSE:6501) has announced that Hitachi developed a new automation technology of 3D culture(2), solving problems of the previous 3D culture using Hitachi's Automated Cell Culture Equipment for iPS cells(3). Automation of both 2D culture(4) and 3D culture using this equipment makes it possible to automatic massive manufacture a variety of cell types such as cardiomyocytes, meeting customer needs. The automation technology was developed by collaborative research with Myoridge Co. Ltd. which has culture technology of iPS cell-derived cardiomyocytes by the protein-free method.
|A schematic diagram of automated new 3D culture*10|
Furthermore the support service to establish an automatic manufacturing process for customers who are considering automation of manufacturing regenerative medicine products will be started on December 1st, 2019. As for the service, Hitachi will examine customers' manual manufacturing process to find out the important parameters, and suggest how to optimize them by the development knowledge of automation technology of 3D culture.
Expanding the market of regenerative medicine to recover the functions of tissues and organs is expected in recent years. A large number of cells are required for regenerative medicine but it is difficult to manufacture an enough amount of cells manually. So the automation technology of mass cell culture is necessary to expand the market of regenerative medicine.
Hitachi had been developing automation technology of mass iPS cell culture, and developed the automated cell culture equipment for iPS cells for research use in June 2017. Adopting the closed flow channel for the connection of the culture vessels and the medium bottles, the equipment is capable of cell seeding, culturing, and monitoring in sterile environment and offers stable supply of high-quality mass cells. Hitachi commercialized the automated cell mass culture equipment which has the necessary functions to comply with the Japanese regulation, GCTP(5) for the first time in Japan(6) in March 2019.(7)
Hitachi automated the new 3D culture (low medium cost, low shear stress(8), and simple medium change process) by collaborating with Myoridge, solving problems of the previous 3D culture. The previous 3D culture has problems such as using a large amount of medium because of the height of the culture reactor, the shear stress to cells from the agitating medium, and the complex process of medium change. Hitachi started the collaborative research with Myoridge in October 2018 and developed the automation technology of the new 3D culture by distributing spheroids both uniformly and densely on the cell culture vessel for 2D culture. Furthermore, Hitachi manufactured cardiomyocytes by the automation technology more effectively than by manual. The technology is probably able to be applied to a variety of cell types and make them be manufactured automatically.
Hitachi also will start the support service to establish an automatic manufacturing process using automated cell culture equipment for iPS cells for customers who are considering automation of manufacturing regenerative medicine products by 2D or 3D culture. Each manufacturing process is different according to cell type. So automation of manufacturing requires to optimize the parameters of the equipment such as the pumping speed of cell suspension(9) and the oscillating angle of culture vessels. As for the service, Hitachi will examine customers' manual manufacturing process to find out the important parameters, and suggest how to optimize them. Hitachi will be able to support the automation of customers' manufacturing process by starting the service.
Hitachi group will contribute to expand the market of regenerative medicine by offering comprehensive solution including automated cell culture equipment, support service to establish an automatic manufacturing process, cell manufacturing facility, related equipment, and contract development and manufacturing services.
(1) Efficiency of differentiation: the rate of differentiated cells from iPS cells to cardiomyocytes
(2) 3D culture is a culture which makes cells to proliferate in all three dimensions forming aggregations.
3D culture promote differentiation to cardiomyocytes, liver cells, and so on, because the environment for 3D culture is similar to in vivo.
(3) Automated Cell Culture Equipment for iPS cells is not a medical device specified by the Pharmaceutical and Medical Device Act (PMD Act) in Japan.
(4) 2D culture is a culture which makes cells to proliferate on the bottoms of culture vessel forming single layer.
(5) GCTP (Good Gene, Cellular, and Tissue-based Products Manufacturing Practice): ordinance on standers for manufacturing control and quality control of regenerative medicine products
(6) Investigated by Hitachi
(7) Hitachi launches Automated Cell Mass Culture Equipment for iPS cells to spread Regenerative Medicine (March 11th, 2019)
(8) Shear stress: stress to cells from wave by agitation
(9) Cell suspension: a mixture of cells and liquid medium
(10) Patent pending in Japan (As of November 26, 2019)
About Hitachi, Ltd.
Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, delivers innovations that answer society's challenges, combining its operational technology, information technology, and products/systems. The company's consolidated revenues for fiscal 2017 (ended March 31, 2018) totaled 9,368.6 billion yen ($88.4 billion). The Hitachi Group is an innovation partner for the IoT era, and it has approximately 307,000 employees worldwide. Through collaborative creation with customers, Hitachi is deploying Social Innovation Business using digital technologies in a broad range of sectors, including Power/Energy, Industry/Distribution/Water, Urban Development, and Finance/Social Infrastructure/Healthcare. For more information on Hitachi, please visit the company's website at http://www.hitachi.com.
Source: Hitachi, Ltd.
Copyright ©2020 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
More Latest Release >>
DOCOMO Releases White Paper Promoting 6G Communication System
Jan 24, 2020 12:00 JST
NEC Develops Millimeter-wave Distributed Antenna Radio Unit Improving the Channel Quality for Indoor 5G Applications
Jan 24, 2020 11:05 JST
Eisai: Dayvigo (Lemborexant) Approved for Treatment of Insomnia in Japan
Jan 23, 2020 15:57 JST
Eisai: Approval of Antiepileptic Drug Fycompa in Japan for Monotherapy and Pediatric Indications for Partial-Onset Seizures, as well as a New Formulation
Jan 23, 2020 15:46 JST
Mitsubishi Corporation Participates in Vietnam's "Grand Park Project"
Jan 23, 2020 12:39 JST
Fujitsu Launches 9 New Enterprise PC Models including Educational Tablets with Improved Ease of Use
Jan 23, 2020 11:14 JST
DOCOMO to Partner with AI-powered Enterprise Meeting Note Provider Otter.ai in Japan
Jan 22, 2020 12:21 JST
DOCOMO to Pursue Collaboration with Skydio, U.S. Manufacturer of Autonomous Drones Capable of Flying without GPS Guidance
Jan 22, 2020 12:00 JST
Mitsubishi Motors concludes a disaster cooperation agreement for the first time in Tokyo with Minato City
Jan 21, 2020 20:04 JST
DOCOMO and DOCOMO ASIA to Provide IoT Solution for YANMAR's SMARTASSIST System in India
Jan 21, 2020 16:13 JST
NEC Highlights 5G-enabled Business Creation and Connectivity at MWC Barcelona 2020
Jan 20, 2020 16:08 JST
Eisai Rated "A", the Highest Rating in the CDP Climate Change Report 2019
Jan 20, 2020 15:21 JST
Fujitsu Group Earns Top Rating in CDP Climate Change Evaluation for Third Year Running
Jan 20, 2020 15:03 JST
Showa Denko to Streamline Domestic Production of Unsaturated Polyester Resin and Vinyl Ester Resin
Jan 20, 2020 12:30 JST
Toyota Indiana Completes $1.3 Billion Modernization Project; Includes 550 New Jobs
Jan 20, 2020 08:46 JST
Toyota Yaris WRC Trio Start a New Chapter with a Classic Challenge
Jan 17, 2020 20:05 JST
DOCOMO Conducts World's First Successful Trial of Transparent Dynamic Metasurface
Jan 17, 2020 16:05 JST
Hitachi Industrial Products Received "EN 15085 Certificate" for Welding of Railway Vehicles and Components
Jan 17, 2020 13:45 JST
Hitachi Completes Construction of H1 TOWER, One of World's Tallest Elevator Test Towers, at R&D and Manufacturing Facility in Guangzhou, China
Jan 17, 2020 09:33 JST
Hitachi Joined WIPO GREEN as a Contributing Partner
Jan 17, 2020 09:07 JST